dimethylglycine and Chronic Kidney Failure studies

dimethylglycine: metabolic product of calcium pangamate; mutagen when mixed with nitrite; RN given refers to parent cpd
N,N-dimethylglycine : An N-methylglycine that is glycine carrying two N-methyl substituents.

Research Excerpts

Excerpt	Relevance	Reference
"Fasting and post-methionine load hyperhomocysteinemia are independent risk factors for vascular disease that are common in chronic renal failure."	9.10	Betaine supplementation decreases post-methionine hyperhomocysteinemia in chronic renal failure. ( Chambers, ST; Dellow, WJ; George, PM; Lever, M; McGregor, DO; Robson, RA, 2002)
"Hyperhomocysteinemia is a risk factor for atherosclerosis that is common in chronic renal failure (CRF), but its cause is unknown."	7.71	Dimethylglycine accumulates in uremia and predicts elevated plasma homocysteine concentrations. ( Chambers, ST; Dellow, WJ; George, PM; Lever, M; McGregor, DO; Robson, RA, 2001)
"Fasting and post-methionine load hyperhomocysteinemia are independent risk factors for vascular disease that are common in chronic renal failure."	5.10	Betaine supplementation decreases post-methionine hyperhomocysteinemia in chronic renal failure. ( Chambers, ST; Dellow, WJ; George, PM; Lever, M; McGregor, DO; Robson, RA, 2002)
"Hyperhomocysteinemia is a risk factor for atherosclerosis that is common in chronic renal failure (CRF), but its cause is unknown."	3.71	Dimethylglycine accumulates in uremia and predicts elevated plasma homocysteine concentrations. ( Chambers, ST; Dellow, WJ; George, PM; Lever, M; McGregor, DO; Robson, RA, 2001)
"Seven pre-dialysis chronic renal failure patients consumed 400 mg of dimethylglycine or placebo daily for 28 days."	2.71	Dimethylglycine supplementation does not affect plasma homocysteine concentrations in pre-dialysis chronic renal failure patients. ( Chambers, ST; George, PM; Lee, MB; Lever, M; McGregor, DO; Slow, S, 2004)

Research

Studies (3)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Urinary Oxalate Excretion

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Slow, S	1
McGregor, DO	3
Lever, M	3
Lee, MB	1
George, PM	3
Chambers, ST	3
Dellow, WJ	2
Robson, RA	2

Trial	Phase	Enrollment	Study Type	Start Date	Status
Efficacy of Betaine for Reduction of Urine Oxalate in Patients With Type 1 Primary Hyperoxaluria[NCT00283387]	Phase 2	15 participants (Actual)	Interventional	2007-02-28	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

"The patients were randomly assigned oral betaine or placebo for 2 months, followed by a 2 month washout. Each patient then received the alternate study medication for 2 months.~Urinary Oxalate Excretion was measured by oxalate oxidase. Two 24 hour urine collections were obtained at baseline, and during the eighth week of each study period." (NCT00283387)
Timeframe: baseline, 2 months, 6 months

Intervention	umol/mg (Mean)
Betaine	1.43
Placebo	1.04

Article	Year
Dimethylglycine supplementation does not affect plasma homocysteine concentrations in pre-dialysis chronic renal failure patients. Clinical biochemistry, 2004, Volume: 37, Issue:11 Topics: Adult; Aged; Betaine; Homocysteine; Humans; Kidney Failure, Chronic; Methionine; Middle Aged; Renal	2004
Betaine supplementation decreases post-methionine hyperhomocysteinemia in chronic renal failure. Kidney international, 2002, Volume: 61, Issue:3 Topics: Aged; Betaine; Cross-Over Studies; Drug Therapy, Combination; Fasting; Female; Folic Acid; Hematinic	2002

dimethylglycine and Chronic Kidney Failure